Population Pharmacokinetics and Exposure-Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer.

ABSTRACT:

Purpose

Paclitaxel liposome (Lipusu) is the first commercialized liposomal formulation of paclitaxel. There has been little data collected on the pharmacokinetics (PK) of paclitaxel liposome, especially in relation to patient use. This study aimed to build a population pharmacokinetic (PopPK) model and further explore the exposure-safety relationship for paclitaxel liposome in patients with non-small cell lung cancer (NSCLC).

Methods

Data from 45 patients with a total of 349 plasma concentrations were analyzed. The PopPK model was built using the non-linear mixed effect modeling technique.

Results

The PK of paclitaxel liposome were well described by a three-compartment model with first-order elimination. For a dose of 175 mg m^-2, the estimated clearance of

SUBMITTER: Zhou H 

PROVIDER: S-EPMC7892953 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature